| Literature DB >> 33274363 |
Varshini Vasudevaraja1, Javier Hernaez Rodriguez1, Cristiana Pelorosso2, Kaicen Zhu1, Anna Maria Buccoliero3, Maristela Onozato4, Hussein Mohamed1, Jonathan Serrano1, Lily Tredwin1, Marianna Garonzi5, Claudio Forcato5, Briana Zeck1, Sitharam Ramaswami1, James Stafford6, Arline Faustin7, Daniel Friedman7, Eveline Teresa Hidalgo8, David Zagzag9, Jane Skok1, Adriana Heguy1, Luis Chiriboga1, Valerio Conti2, Renzo Guerrini9, A John Iafrate4, Orrin Devinsky7,8,9, Aristotelis Tsirigos1, John G Golfinos9, Matija Snuderl1.
Abstract
Epilepsy is a heterogenous group of disorders defined by recurrent seizure activity due to abnormal synchronized activity of neurons. A growing number of epilepsy cases are believed to be caused by genetic factors and copy number variants (CNV) contribute to up to 5% of epilepsy cases. However, CNVs in epilepsy are usually large deletions or duplications involving multiple neurodevelopmental genes. In patients who underwent seizure focus resection for treatment-resistant epilepsy, whole genome DNA methylation profiling identified 3 main clusters of which one showed strong association with receptor tyrosine kinase (RTK) genes. We identified focal copy number gains involving epidermal growth factor receptor (EGFR) and PDGFRA loci. The dysplastic neurons of cases with amplifications showed marked overexpression of EGFR and PDGFRA, while glial and endothelial cells were negative. Targeted sequencing of regulatory regions and DNA methylation analysis revealed that only enhancer regions of EGFR and gene promoter of PDGFRA were amplified, while coding regions did not show copy number abnormalities or somatic mutations. Somatic focal copy number gains of noncoding regulatory represent a previously unrecognized genetic driver in epilepsy and a mechanism of abnormal activation of RTK genes. Upregulated RTKs provide a potential avenue for therapy in seizure disorders.Entities:
Keywords: DNA methylation; EGFR; Enhancers; Epilepsy; PDGFRA; Somatic mutations
Mesh:
Substances:
Year: 2021 PMID: 33274363 PMCID: PMC8502434 DOI: 10.1093/jnen/nlaa137
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.685